PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET
Company Participants
Ron Aldridge – Senior Director of Investor Relations
Matthew Klein - Chief Executive Officer
Eric Pauwels - Chief Business Officer
Kylie O’Keefe - Chief Commercial Officer
Pierre Gravier - Chief Financial Officer
Conference Call Participants
Kristen Kluska - Cantor Fitzgerald
Eric Joseph – J.P. Morgan
Kelly Shi – Jefferies
Samantha Corwin - William Blair
Brian Abraham - RBC Capital Markets
Joseph Thome - TD Cowen
Jeff Hung - Morgan Stanley
Gena Wang – Barclays
David Lebowitz – Citi
Joseph Schwartz - Leerink Partners
Operator
Good day and thank you for standing by. Welcome to PTC Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Ron Aldridge, Senior Director of Investor Relations.
Ron Aldridge
Good afternoon and thank you for joining us today to discuss PTC Therapeutics second quarter 2024 corporate update and financial results. I'm joined today by our Chief Executive Officer, Dr. Matthew Klein, our Chief Business Officer, Eric Pauwels; our Chief Commercial Officer, Kylie O'Keefe; and our Chief Financial Officer, Pierre Gravier.
Today's call will include forward-looking statements based on our current expectations. Please take a moment to review the slide posted on our Investor Relations website in conjunction with the call which contains our forward-looking statements. Our actual results could materially differ from these forward-looking statements as such statements are subject to risks that can materially and adversely affect our business and results of operations. For a detailed description of applicable risks and uncertainties, we encourage you to review the company's most recent quarterly report on Form 10-Q and annual report on Form 10-K filed with the Securities and Exchange Commission as well as the company's other SEC filings.
We will disclose certain non-GAAP information during this call. Information regarding our use of GAAP to non-GAAP financial measures and a reconciliation of GAAP to non-GAAP are available in today's earnings release.
With that, let me pass the call over to our CEO, Dr. Matthew Klein. Matt?
Matthew Klein
Thank you, Jane. Good afternoon and thank you all for joining the call. I'm pleased to share with you our second quarter 2024 financial results and to provide an update on the progress of our development programs. As we have discussed, our focus for 2024 is on execution.